Publications by authors named "P J DiPiro"
Rationale And Objectives: To investigate patient, examination, and system factors associated with follow-up completion for probably benign breast (BI-RADS 3) findings.
Materials And Methods: Retrospective review identified all BI-RADS 3 mammography, ultrasound, and MRI reports (index studies) for unique patient encounters at a large multi-institution Health Care System Jan 1-Dec 31, 2021. Electronic health record supplied patient demographics and examination type; Radiology Information System supplied ordering and scheduling information.
Objective: Determine the rate of documented notification, via an alert, for intra-institutional discrepant radiologist opinions and addended reports and resulting clinical management changes.
Methods: This institutional review board-exempt, retrospective study was performed at a large academic medical center. We defined an intra-institutional discrepant opinion as when a consultant radiologist provides a different interpretation from that formally rendered by a colleague at our institution.
Purpose: To compare thoracic and abdominal radiologists' follow-up recommendations for abdominal findings identified on chest CT.
Methods: This Institutional Review Board-exempt, retrospective study was performed at a large academic medical center with subspecialty radiology divisions. We used a combination of natural language processing and manual reviews to identify chest CT reports with and without abdominal findings that were interpreted by thoracic radiologists in 2019.
Article Synopsis
- Brain metastases can affect up to 50% of patients with HER2-positive breast cancer, but past trials mostly excluded those with active brain metastases, leading to limited understanding of the antibody-drug conjugate T-DXd's effectiveness in this area.
- T-DXd was tested in both patient-derived xenografts of HER2-positive and HER2-low breast cancer brain metastases and a retrospective study of 17 patients, showing significant tumor growth inhibition and improved survival rates.
- Results indicated a 73% CNS objective response rate in patients with primarily HER2-positive brain metastases, suggesting promising CNS activity of T-DXd and the need for future clinical trials to assess its efficacy further.